
Neuland Laboratories Ltd Surges on High-Value Trading and Institutional Interest
2026-08-06 10:00:08Neuland Laboratories Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, witnessed a remarkable surge in trading activity on 6 August 2026, driven by substantial value turnover and heightened institutional participation. The stock outperformed its sector peers and broader market indices, reflecting renewed investor confidence and robust market dynamics.
Read full news article
Broad-Based Technical Strength Lifts Neuland Laboratories Ltd to 52-Week High of Rs 21850
2026-08-06 09:54:45Surging past its previous peaks, Neuland Laboratories Ltd touched a new 52-week high of Rs 21,850 on 6 Aug 2026, propelled by a confluence of robust technical indicators and sustained price momentum that has captivated market attention.
Read full news article
Neuland Laboratories Ltd Surges 7.95% to Day's High of Rs 21,850 — Outperforms Sector by 6.96 Percentage Points
2026-08-06 09:47:04The Sensex edged up 0.23% on 6 Aug 2026, while Neuland Laboratories Ltd surged 7.95%, reaching an intraday high of Rs 21,850. This 6.96-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a broad market lift.
Read full news article
Neuland Laboratories Ltd Hits All-Time High of Rs 21,850 as Momentum Builds Across Timeframes
2026-08-06 09:31:31Extending its recent rally, Neuland Laboratories Ltd surged to a fresh all-time high of Rs 21,850 on 6 Aug 2026, outperforming its sector and the broader market with a robust 6.82% gain on the day.
Read full news article
Neuland Laboratories Q1 FY27: Spectacular 962% Profit Surge Masks Margin Compression Concerns
2026-08-05 21:31:05Neuland Laboratories Ltd., a Hyderabad-based pharmaceutical manufacturer specialising in active pharmaceutical ingredients (APIs), has delivered a stunning Q1 FY27 performance with net profit surging 962.37% year-on-year to ₹147.67 crores, though the sequential decline of 30.56% from Q4 FY26's exceptional ₹212.67 crores raises questions about sustainability. The ₹25,414-crore market capitalisation company saw its stock rally 3.51% to ₹19,964.70 following the results announcement, trading near its 52-week high of ₹20,100.00 and reflecting investor optimism about the pharma sector's recovery trajectory.
Read full news article
Broad-Based Technical Strength Lifts Neuland Laboratories Ltd to 52-Week High of Rs 20,072
2026-08-05 15:35:45With a 56.7% gain over the past year, Neuland Laboratories Ltd has surged to a fresh 52-week high of Rs 20,072 on 5 Aug 2026, outpacing the Sensex which declined by 2.6% over the same period. This milestone caps a sustained rally fuelled by a confluence of strong technical signals and robust quarterly earnings growth.
Read full news article
Neuland Laboratories Ltd is Rated Buy
2026-07-27 10:10:04Neuland Laboratories Ltd is rated Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 27 July 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news articleShareholder Meeting / Postal Ballot-Outcome of AGM
04-Aug-2026 | Source : BSEVoting Results Scrutinizer Report and proceeding of 42nd Annual General Meeting held on August 4 2026
Shareholder Meeting / Postal Ballot-Scrutinizers Report
04-Aug-2026 | Source : BSEVoting Results Scrutinizer Report and proceedings of 42nd Annual General Meeting held on August 4 2026
Intimation Under Regulation 30 Of SEBI Listing Regulations
31-Jul-2026 | Source : BSEIntimation under Regulation 30 of SEBI Listing Regulations
Corporate Actions
No Upcoming Board Meetings
Neuland Laboratories Ltd has declared 340% dividend, ex-date: 24 Jul 26
No Splits history available
No Bonus history available
Neuland Laboratories Ltd has announced 4:25 rights issue, ex-date: 13 Aug 14








